Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

AbbVie Inc

4AB
Current price
153.08 EUR -0.08 EUR (-0.05%)
Last closed 153.16 EUR
Sector Healthcare
Industry Drug Manufacturers - General
Exchange XETRA Stock Exchange
Capitalization 273 201 889 280 EUR
Yield for 12 month +23.35 %
1Y
3Y
5Y
10Y
15Y
4AB
21.11.2021 - 28.11.2021

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. Address: 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

P/E ratio

49.2219

Dividend Yield

3.77 %

Current Year

+50 106 562 506 EUR

Last Year

+53 552 899 218 EUR

Current Quarter

+11 355 568 770 EUR

Last Quarter

+13 192 200 567 EUR

Current Year

+31 274 398 701 EUR

Last Year

+37 489 058 880 EUR

Current Quarter

+7 578 988 872 EUR

Last Quarter

+7 930 448 799 EUR

Key Figures 4AB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 26 115 999 744 EUR
Operating Margin TTM 28.29 %
PE Ratio 49.2219
Return On Assets TTM 7.71 %
PEG Ratio 0.4518
Return On Equity TTM 56.24 %
Wall Street Target Price
Revenue TTM 54 402 998 272 EUR
Book Value 4.54 EUR
Revenue Per Share TTM
Dividend Share 6.06 EUR
Quarterly Revenue Growth YOY 0.7 %
Dividend Yield 3.77 %
Gross Profit TTM 41 527 000 000 EUR
Earnings per share 3.11 EUR
Diluted Eps TTM 3.11 EUR
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY 496.4 %
Profit Margin 11.02 %

Dividend Analytics 4AB

Dividend growth over 5 years

78 %

Continuous growth

7 years

Payout Ratio 5 years average

127 %

Dividend History 4AB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate 5.77
Ex Dividend Date 15.07.2024
Forward Annual Dividend Yield 3.77 %
Last Split Factor
Payout Ratio 1.94 %
Last Split Date
Dividend Date

Stock Valuation 4AB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 49.2219
Forward PE 14.6843
Enterprise Value Revenue 5.731
Price Sales TTM 4.9647
Enterprise Value EBITDA 18.1282
Price Book MRQ 27.9207

Financials 4AB

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators 4AB

For 52 weeks

115.18 EUR 167.25 EUR
50 Day MA 152.43 EUR
Shares Short Prior Month
200 Day MA 149.25 EUR
Short Ratio
Shares Short
Short Percent

Dynamics of changes in the value of assets

N

NFC1

17.80 EUR NETFLIX INC. CDR 0 (0%)
Detailed analytics
L

LFL

0.44 EUR LATAM Airlines Group SA ADR +0.02 (+4.76%)
Detailed analytics
N

NFC

638.70 EUR Netflix Inc +9.95 (+1.46%)
Detailed analytics
N

NFLX

690.65 USD Netflix Inc +8.14 (+1.19%)
Detailed analytics
ABBV

ABBV

167.25 USD AbbVie Inc +2.53 (+1.54%)
Detailed analytics